NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc., (NASDAQ: TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that it has received necessary regulatory permits in Canada and Germany to export medical cannabis flower for distribution to German patients.
Tilray previously announced the first-ever export of medical cannabis oil to Germany for nationwide distribution in pharmacies. Tilray’s full-spectrum cannabis extracts became available in German pharmacies nationwide through partnerships with leading German pharmaceutical wholesalers NOWEDA, GEHE, Alliance Healthcare, Pharma Privat and Phoenix in cooperation with pharma logistics partner Paesel + Lorei.
The export of Tilray’s whole flower medical cannabis products will make Tilray the first and only medical cannabis company with a differentiated product offering of both full-spectrum oils and whole flower, including some of the highest potency products available in the German medical market. Certain patient populations with specialized conditions require higher potency THC medical cannabis as treatment. These patients will now have access to products that were previously unavailable to them in this market.
“Today’s announcement marks another milestone for Tilray as we expand operations in the European Union,” said Brendan Kennedy, Chief Executive Officer, Tilray. “We are proud to be able to offer access to differentiated high-quality, pharmaceutical-grade medical cannabis products to patients in need.”
Tilray became the first medical cannabis producer in North America to be GMP certified in December 2016. GMP certification is the most rigorous standard that manufacturers of medical products can meet in their production processes, and it is intended to provide regulators and health care providers in countries new to medical cannabis with certainty that Tilray products are the safe and smart choice. GMP certification is enabling Tilray to expand the international distribution of its products.
More details on how patients in Germany can access Tilray’s whole flower products will be released later this year.
Tilray is a global pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids currently serving tens of thousands of patients in eleven countries spanning five continents.